A ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP of the European Pharmacopoeia monograph is often referred to as a ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE Certificate of Suitability (COS). The purpose of a ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE to their clients by showing that a ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP has been issued for it. The manufacturer submits a ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP (COS) as part of the market authorization procedure, and it takes on the role of a ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP holder for the record. Additionally, the data presented in the ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE DMF.
A ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE suppliers with CEP (COS) on PharmaCompass.